These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

744 related items for PubMed ID: 27792012

  • 21. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease.
    Zhang H, Therriault J, Kang MS, Ng KP, Pascoal TA, Rosa-Neto P, Gauthier S, Alzheimer’s Disease Neuroimaging Initiative.
    Alzheimers Res Ther; 2018 Aug 16; 10(1):80. PubMed ID: 30115118
    [Abstract] [Full Text] [Related]

  • 22. Amyloid-β PET-Correlation with cerebrospinal fluid biomarkers and prediction of Alzheimer´s disease diagnosis in a memory clinic.
    Müller EG, Edwin TH, Stokke C, Navelsaker SS, Babovic A, Bogdanovic N, Knapskog AB, Revheim ME.
    PLoS One; 2019 Aug 16; 14(8):e0221365. PubMed ID: 31430334
    [Abstract] [Full Text] [Related]

  • 23. Concordance of Lumipulse cerebrospinal fluid t-tau/Aβ42 ratio with amyloid PET status.
    Kaplow J, Vandijck M, Gray J, Kanekiyo M, Huyck E, Traynham CJ, Esquivel R, Fagan AM, Luthman J.
    Alzheimers Dement; 2020 Jan 16; 16(1):144-152. PubMed ID: 31914216
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Analytical and Clinical Performance of Amyloid-Beta Peptides Measurements in CSF of ADNIGO/2 Participants by an LC-MS/MS Reference Method.
    Korecka M, Figurski MJ, Landau SM, Brylska M, Alexander J, Blennow K, Zetterberg H, Jagust WJ, Trojanowski JQ, Shaw LM, Alzheimer’s Disease Neuroimaging Initiative.
    Clin Chem; 2020 Apr 01; 66(4):587-597. PubMed ID: 32087019
    [Abstract] [Full Text] [Related]

  • 27. Amyloid-β 42/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer's disease: validation of two novel assays.
    Lewczuk P, Lelental N, Spitzer P, Maler JM, Kornhuber J.
    J Alzheimers Dis; 2015 Apr 01; 43(1):183-91. PubMed ID: 25079805
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Amyloid PETs are commonly negative in suspected Alzheimer's disease with an increase in CSF phosphorylated-tau protein concentration but an Aβ42 concentration in the very high range: a prospective study.
    Manca C, Rivasseau Jonveaux T, Roch V, Marie PY, Karcher G, Lamiral Z, Malaplate C, Verger A.
    J Neurol; 2019 Jul 01; 266(7):1685-1692. PubMed ID: 30963253
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Use of amyloid-PET to determine cutpoints for CSF markers: A multicenter study.
    Zwan MD, Rinne JO, Hasselbalch SG, Nordberg A, Lleó A, Herukka SK, Soininen H, Law I, Bahl JM, Carter SF, Fortea J, Blesa R, Teunissen CE, Bouwman FH, van Berckel BN, Visser PJ.
    Neurology; 2016 Jan 05; 86(1):50-8. PubMed ID: 26468410
    [Abstract] [Full Text] [Related]

  • 35. Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers.
    Salvadó G, Molinuevo JL, Brugulat-Serrat A, Falcon C, Grau-Rivera O, Suárez-Calvet M, Pavia J, Niñerola-Baizán A, Perissinotti A, Lomeña F, Minguillon C, Fauria K, Zetterberg H, Blennow K, Gispert JD, Alzheimer’s Disease Neuroimaging Initiative, for the ALFA Study.
    Alzheimers Res Ther; 2019 Mar 21; 11(1):27. PubMed ID: 30902090
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease.
    Vlassenko AG, McCue L, Jasielec MS, Su Y, Gordon BA, Xiong C, Holtzman DM, Benzinger TL, Morris JC, Fagan AM.
    Ann Neurol; 2016 Sep 21; 80(3):379-87. PubMed ID: 27398953
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease.
    Tarawneh R, D'Angelo G, Crimmins D, Herries E, Griest T, Fagan AM, Zipfel GJ, Ladenson JH, Morris JC, Holtzman DM.
    JAMA Neurol; 2016 May 01; 73(5):561-71. PubMed ID: 27018940
    [Abstract] [Full Text] [Related]

  • 40. Proximity to Parental Symptom Onset and Amyloid-β Burden in Sporadic Alzheimer Disease.
    Villeneuve S, Vogel JW, Gonneaud J, Pichet Binette A, Rosa-Neto P, Gauthier S, Bateman RJ, Fagan AM, Morris JC, Benzinger TLS, Johnson SC, Breitner JCS, Poirier J, Presymptomatic Evaluation of Novel or Experimental Treatments for Alzheimer Disease (PREVENT-AD) Research Group.
    JAMA Neurol; 2018 May 01; 75(5):608-619. PubMed ID: 29482212
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 38.